Shareholder Information

Ownership Structure

As of 31 December 2009 there are 89,937,594 outstanding shares in three classes as follows:

14,146,128 A ordinary shares
51,400,865 B preferred ordinary shares
24,390,601 C preferred ordinary shares
89,937,594 Total

To assist in the recruitment, retention and incentive of management, employees, consultants and directors, the Company has established a warrant scheme which enables such individuals to have a share of the increase in value of the business they help create. On 31 December 2009 the Company had 16,468,173 warrants outstanding of which 12,768,756 were exercisable, and further to this the Board of Directors is authorized to grant an additional 1,645,409 warrants to management, employees, consultants and directors.

If the above mentioned warrant scheme totaling 18,113,582 warrants is fully issued and exercised the total number of shares issued and outstanding will be 108,051,176.

The following shareholders hold more than 5% of the share capital outstanding:

  • Coöperatieve AAC LS U.A., Gooimeer 2-35, 1411 DC Naarden, Netherlands
  • LD Pension & LD Dyrtidsfond, Vendersgade 28, 1363 Copenhagen K, Denmark
  • Novo A/S, Krogshøjvej 41, 2880 Bagsværd, Denmark
  • Sunstone Life Science Ventures Fund I K/S, Lautrupsgade 7, 5, 2100 København Ø, Denmark
  • Coöperatieve Gilde Healthcare II U.A., Newtonlaan 91, 3508 AB Utrecht, Netherlands
  • Sunstone BV-III, Lautrupsgade 7, 5, 2100 København Ø, Denmark
  • Pfizer (Wyeth), 5 Giralda Farms, Madison, New Jersey 07940, USA

Contact Person and Additional Information

For further information on the Company's progress, technologies and announcements, please see the Santaris Pharma A/S website at www.santaris.com. For additional information, please e-mail VP & Chief Financial Officer Henrik Stage at hs@santaris.com or Director, Global Communications Navjot Rai at navjot.rai@santaris.com.